Clinical trial NCT05081765 - References

Ovary Cancer — The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib

Citation(s)

•   Debska S, Kubicka J, Czyzykowski R, Habib M, Potemski P
  [PARP inhibitors--theoretical basis and clinical application]. Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.
•   Dostalek M, Akhlaghi F, Puzanovova M
  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012 Aug 1;51(8):481-99. doi: 10.2165/11631900-000000000-00000. Review.
•   Dostalek M, Court MH, Yan B, Akhlaghi F
  Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol. 2011 Jul;163(5):937-47. doi: 10.1111/j.1476-5381.2011.01270.x.
•   Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J
  Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia Pac J Clin Oncol. 2016 Dec;12(4):323-331. doi: 10.1111/ajco.12636. Review. Erratum in: Asia Pac J Clin Oncol. 2017 Aug;13(4):337.
•   Karbownik A, Stachowiak A, Urjasz H, Sobanska K, Szczecinska A, Grabowski T, Stanislawiak-Rudowicz J, Wolc A, Grzeskowiak E, Szalek E
  The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats. Pharmacol Rep. 2020 Feb;72(1):254-259. doi: 10.1007/s43440-019-00021-0. Epub 2020 Jan 8. Erratum in: Pharmacol Rep. 2021 Oct;73(5):1483.
•   Karbownik A, Szalek E, Sobanska K, Grabowski T, Wolc A, Grzeskowiak E
  The alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbits. Pharmacol Rep. 2016 Oct;68(5):964-8. doi: 10.1016/j.pharep.2016.04.015. Epub 2016 May 6.
•   Karbownik A, Szalek E, Sobanska K, Klupczynska A, Plewa S, Grabowski T, Wolc A, Moch M, Kokot ZJ, Grzeskowiak E
  A pharmacokinetic study on lapatinib in type 2 diabetic rats. Pharmacol Rep. 2018 Apr;70(2):191-195. doi: 10.1016/j.pharep.2017.09.003. Epub 2017 Sep 18.
•   Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U
  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31. Erratum in: Lancet Oncol. 2015 Apr;16(4):e158.
•   Porazka J, Szalek E, Polom W, Czajkowski M, Grabowski T, Matuszewski M, Grzeskowiak E
  Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration. Eur J Drug Metab Pharmacokinet. 2019 Aug;44(4):579-584. doi: 10.1007/s13318-019-00543-1.
•   Stachowiak A, Szalek E, Karbownik A, Lojko A, Porazka J, Przewozna I, Grabowski T, Wolc A, Grzeskowiak E
  The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):289-294. doi: 10.1007/s13318-018-0508-4.
•   Szalek E, Karbownik A, Sobanska K, Grabowski T, Polom W, Lewandowska M, Wolc A, Matuszewski M, Grzeskowiak E
  The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. Pharmacol Rep. 2014 Oct;66(5):892-6. doi: 10.1016/j.pharep.2014.05.011. Epub 2014 Jun 6.
•   Tran M, Elbarbry F
  Influence of diabetes mellitus on pharmacokinetics of drugs. MOJ Bioequiv Availab. 2016;2(1):3-4.
•   Wisnik E, Ryksa M, Koter-Michalak M
  [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective]. Postepy Hig Med Dosw (Online). 2016 Apr 13;70:280-94. Review. Polish.

The Effect of Glucose Level and Diabetes Mellitus on the Plasma Minimum Steady-state Concentration Ctrough of Olaparib in Patients With Ovarian Cancer

Details for clinical trial NCT05081765